PMV Pharmaceuticals
PMVP
73 hedge funds and large institutions have $2.33B invested in PMV Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 14 closing their positions.
157% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 14
114% more capital invested
Capital invested by funds: $1.09B → $2.33B (+$1.25B)
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
73% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 11
43% more funds holding
Funds holding: 51 → 73 (+22)
12.77% more ownership
Funds ownership: 72.59% → 85.36% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$44.7M |
| 2 |
BlackRock
New York
|
+$31.5M |
| 3 |
Alkeon Capital Management
New York
|
+$25.6M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$19.6M |
| 5 |
PA
Perceptive Advisors
New York
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.4M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$12.8M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$10.9M |
| 4 |
AG
Artal Group
Luxembourg
|
-$7.1M |
| 5 |
UBS AM
Chicago,
Illinois
|
-$6.09M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AG
76
Artal Group
Luxembourg
| – | -$7.1M | -200,000 | Closed |
|
77
Goldman Sachs
New York
| – | -$5.96M | -167,751 | Closed |
|
|
APM
78
Avidity Partners Management
Dallas,
Texas
| – | -$5.33M | -150,000 | Closed |
|
|
OMC
79
Old Mission Capital
Chicago,
Illinois
| – | -$1.83M | -51,700 | Closed |
|
80
Holocene Advisors
New York
| – | -$1.77M | -50,000 | Closed |
|
81
Jane Street
New York
| – | -$1.11M | -31,349 | Closed |
|
|
PCM
82
Pinz Capital Management
New York
| – | -$987K | -27,814 | Closed |
|
83
Squarepoint
New York
| – | -$787K | -22,156 | Closed |
|
|
AGM
84
Alpine Global Management
New York
| – | -$415K | -11,701 | Closed |
|
|
PHK
85
Point72 Hong Kong
Hong Kong
| – | -$223K | -6,291 | Closed |
|
|
MS
86
Maven Securities
St Helier,
Jersey
| – | -$200K | -5,000 | Closed |
|
|
SCM
87
Sio Capital Management
New York
| – | -$36K | -1,000 | Closed |
|
PMVP Hedge Fund Activity: Q4 2020 in Review
73 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q4 2020, worth a combined $2.33B — up 114% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new PMVP positions and 14 closed out — a net gain of 22 holders — while 19 added to existing stakes and 11 trimmed.
The largest buyer was Vanguard Group, adding an estimated $44.7M. The largest seller was Wellington Management Group, cutting an estimated $13.4M.
- 73 institutional investors held PMV Pharmaceuticals (PMVP) as of Q4 2020, up from 51 in Q3 2020.
- Funds reported $2.33B of PMV Pharmaceuticals stock for Q4 2020, up 114% quarter-over-quarter.
- 36 funds opened new PMV Pharmaceuticals positions in Q4 2020 and 14 closed out, a net change of +22 holders.
- The largest PMV Pharmaceuticals buyer in Q4 2020 was Vanguard Group, an estimated $44.7M added.
- The largest PMV Pharmaceuticals seller in Q4 2020 was Wellington Management Group, an estimated $13.4M sold.
Based on aggregated 13F filings for Q4 2020.